Angioimmunoblastic T-cell lymphoma (AILD) is considered a variety of T-cell lymphoma, which usually occurs in adults. Symptoms include generalized lymphadenopathy (enlarged lymph nodes) and increased antibody proteins in the blood (hypergammaglobinemia). Other symptoms are fever, skin rash and weight loss. It is classified under periphreal T-cell lymphomas.
Characterized by clonal T-cell receptor gene rearrangement, this entity is managed like diffuse large cell lymphoma. Myeloablative chemotherapy and radiation therapy with autologous peripheral stem cell support has been described in anecdotal reports or as a part of populations of T-cell lymphoma patients treated with transplantation. NCCN lists both autologous and allogeneic(p. T-CELL 5) as an option. The British Standards for Hematology 2008 guideline says: “Consolidation with auto-HSCT should be considered for chemosensitive disease in first remission or after relapse LEVEL IV GRADE C”.
Tetsuo Yamazaki, Umihiko Sawada, Yoshimasa Kura, Takeyoshi Ito, Jin Takeuchi, Yoshihiro Hatta, Shingo Aikawa, Kazuhiro Takei, Hikaru Ishizuka, Minoru Saiki, Kumi Uenogawa
Lymphoma with a Dose-Intensified CHOP Regimen Followed by High-Dose Chemotherapy
A Single Institution Study Acta Haematologica 2006;116:90-95
Alizadeh AA1, Advani RH. Evaluation and management of angioimmunoblastic T-cell lymphoma: a review of current approaches and future strategies. Clin Adv Hematol Oncol. 2008 Dec;6(12):899-909
Reimer P, Schertlin T, Rüdiger T, et al.: Myeloablative radiochemotherapy followed by autologous peripheral blood stem cell transplantation as first-line therapy in peripheral T-cell lymphomas: first results of a prospective multicenter study. Hematol J 5 (4): 304-11, 2004.